心房颤动患者服用利伐沙班致出血的研究进展
姚娟 - Advances in Clinical Medicine, 2023 - hanspub.org
… and extremely high peak concentrations of rivaroxaban. This study presents the current
progress through a systematic review of domestic and foreign studies of rivaroxaban. …
progress through a systematic review of domestic and foreign studies of rivaroxaban. …
抗凝药物在经颈静脉肝内门体分流术后的应用
蒋明远， 黄华， 路明亮， 林凡榆， 张映媛 - 临床肝胆病杂志, 2018 - lcgdbzz.org
… Compare anticoagulation effects of rivaroxaban with low molecular weight heparin in patients
after transjugular intrahepatic portasystemic stent shunt[J].Chin J New Drugs Clin Remed, …
after transjugular intrahepatic portasystemic stent shunt[J].Chin J New Drugs Clin Remed, …
[HTML][HTML] 新型口服抗凝药在肝硬化合并门静脉血栓的治疗进展
周好男， 陈以宽 - Advances in Clinical Medicine, 2023 - hanspub.org
: 门静脉血栓(PVT) 是肝硬化患者的常见并发症, 可合并腹水, 凝血功能异常, 静脉曲张出血等. 目前
抗凝治疗作为一线治疗. 与传统抗凝药相比, 新型口服抗凝药具有起效快, 不需要常规监测, 食物…
抗凝治疗作为一线治疗. 与传统抗凝药相比, 新型口服抗凝药具有起效快, 不需要常规监测, 食物…
[HTML][HTML] 肝硬化合并门静脉血栓的抗凝治疗进展
杨智炜， 吴斌 - 新医学, 2018 - xinyixue.cn
… 因子Xa或凝血因子Ⅱa,通过抑制其活性来发挥抗凝作用.在美国已上市的NOAC包括凝血因子
Ⅱa抑制剂达比加群(dabigatran)和凝血因子Xa抑制剂阿哌沙班(apixaban),利伐沙班(rivaroxaban)…
Ⅱa抑制剂达比加群(dabigatran)和凝血因子Xa抑制剂阿哌沙班(apixaban),利伐沙班(rivaroxaban)…
心房颤动患者使用新型口服抗凝药有效性和安全性的网状Meta 分析
霍礼超， 李梦丽， 宋明惠， 张彦霞， 薛鹏龙， 乔成栋 - 中国全科医学, 2019 - chinagp.net
… ,ximelagatran, rivaroxaban,xarelto,apixaban,edoxaban,… The long-term multicenter
observational study of dabigatran … AF trial (rivaroxaban once-daily oral direct factor Xa inhibition …
observational study of dabigatran … AF trial (rivaroxaban once-daily oral direct factor Xa inhibition …
[HTML][HTML] 非瓣膜性心房颤动口服抗凝药物临床应用研究进展
朱虹， 赵德斌， 施蕾， 李红 - Advances in Clinical Medicine, 2024 - hanspub.org
… VKAs主要是华法林(warfarin),DOACs包括直接凝血酶抑制剂(direct thrombin inhibitor, DTI)达
比加群酯(dabigatran),以及直接凝血因子Xa抑制剂利伐沙班(rivaroxaban),阿哌沙班(apixaban),…
比加群酯(dabigatran),以及直接凝血因子Xa抑制剂利伐沙班(rivaroxaban),阿哌沙班(apixaban),…
[PDF][PDF] 利伐沙班和达比加群酯对非瓣膜性心房颤动合并糖尿病患者抗凝治疗的有效性与安全性*
曹博， 陈敏， 徐蓝， 姚星烂， 庄月园 - 医药导报, 2023 - yydbzz.com
… : the Rivaroxaban Oncedailyꎬ Oralꎬ Direct Factor Xa Inhibition … :Meta-analysis of
observational studies[J].Cardiovasc … report from the euro observational research programme pilot …
observational studies[J].Cardiovasc … report from the euro observational research programme pilot …
新型口服抗凝药物在非瓣膜性心房颤动患者中的应用及挑战
刘岳， 任怡荣， 朱火兰， 汪芳 - 中国全科医学, 2020 - chinagp.net
… observational study of dabigatran treatment in patients with atrial fibrillation(RELY-ABLE)
study… nonvalvular atrial fibrillation under dabigatran and rivaroxaban therapy:an affordable and …
study… nonvalvular atrial fibrillation under dabigatran and rivaroxaban therapy:an affordable and …
儿童急性淋巴细胞白血病合并血栓栓塞研究进展
李贝多， 邵静波 - 临床儿科杂志, 2022 - jcp.xinhuamed.com.cn
… Systemic endotoxin activity correlates with clot formation: an observational study in patients
with early systemic inflammation and sepsis [J]. Crit Care, 2013, 17(5): R198. [15] Li T, Peng …
with early systemic inflammation and sepsis [J]. Crit Care, 2013, 17(5): R198. [15] Li T, Peng …
冠心病伴慢性肾脏病患者抗栓治疗的研究进展
朱贵家， 樊瑛， 杨树森 - 临床心血管病杂志, 2014 - whuhzzs.com
… Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy
after acute coronarysyndrome:results of the Apixaban for Prevention of Acute Ischemic and …
after acute coronarysyndrome:results of the Apixaban for Prevention of Acute Ischemic and …